The National Health Surveillance Agency (Anvisa) authorized this Thursday (16) the use of Pfizer’s Covid-19 vaccine in children aged 5 to 11 years. The decision is a response to the analysis requested by the pharmaceutical on November 12th.
According to the agency, children under 12 years old should receive doses with only a third of the amount applied to the rest of the public. For this, Pfizer should produce different bottles to differentiate the groups, being used the orange color for children and purple for teenagers and adults.
read more:
Even before formalizing the request for analysis, specialists from Pfizer and Anvisa met to talk about the agenda and discuss technical data regarding the immunizing agent. The analysis, however, began three days later, when the request was formalized.
Before approving the measure, Anvisa requested additional data from the pharmacist and, after receiving the material, held a meeting with specialists in immunology and pediatrics. Representatives of the Brazilian Society of Infectious Diseases (SBI), the Brazilian Society of Pulmonology and Phthisiology (SBPT), the Brazilian Society of Pediatrics (SBP) and the Brazilian Society of Immunizations (SBIm) participated in the decision.
The application of Pfizer’s vaccine to children was also approved by the regulatory agency of the European Union and, on an emergency basis, by the regulatory agency of the United States.
According to the European Medicines Agency (EMA), the side effects of the immunizing agent are similar in children and adults: “Injection site pain, tiredness, headache, redness and swelling at the injection site, muscle aches and chills” .
The statement also says that “these effects are generally mild or moderate and improve a few days after vaccination.”
Source: Full News
The National Health Surveillance Agency (Anvisa) authorized this Thursday (16) the use of Pfizer’s Covid-19 vaccine in children aged 5 to 11 years. The decision is a response to the analysis requested by the pharmaceutical on November 12th.
According to the agency, children under 12 years old should receive doses with only a third of the amount applied to the rest of the public. For this, Pfizer should produce different bottles to differentiate the groups, being used the orange color for children and purple for teenagers and adults.
read more:
Even before formalizing the request for analysis, specialists from Pfizer and Anvisa met to talk about the agenda and discuss technical data regarding the immunizing agent. The analysis, however, began three days later, when the request was formalized.
Before approving the measure, Anvisa requested additional data from the pharmacist and, after receiving the material, held a meeting with specialists in immunology and pediatrics. Representatives of the Brazilian Society of Infectious Diseases (SBI), the Brazilian Society of Pulmonology and Phthisiology (SBPT), the Brazilian Society of Pediatrics (SBP) and the Brazilian Society of Immunizations (SBIm) participated in the decision.
The application of Pfizer’s vaccine to children was also approved by the regulatory agency of the European Union and, on an emergency basis, by the regulatory agency of the United States.
According to the European Medicines Agency (EMA), the side effects of the immunizing agent are similar in children and adults: “Injection site pain, tiredness, headache, redness and swelling at the injection site, muscle aches and chills” .
The statement also says that “these effects are generally mild or moderate and improve a few days after vaccination.”
Source: Full News
